NasdaqGS:RAREBiotechs
Ultragenyx Pharmaceutical (RARE) On Rare Disease Growth Narrative And Why Valuation Is Back In Focus
Ultragenyx Pharmaceutical (RARE) stock continues to trade with recent moves shaped largely by its rare disease portfolio and late stage pipeline. This has prompted investors to reassess risk, growth potential, and current valuation.
See our latest analysis for Ultragenyx Pharmaceutical.
At a share price of $29.28, Ultragenyx Pharmaceutical has seen short term pressure, with a 1 day share price return down 3.11% and 7 day share price return down 13.42%. This is set against a 90 day share price...